Background: Chronic hepatitis C (CHC) is an important liver disease, which may progress to cirrhosis or hepatocellular carcinoma. The current treatment regimen for CHC includes pegylated interferon-α (PEG-IFN) combined with ribavirin Ferritin is the major iron storage protein and provides an indirect estimate of the body's iron stores. It is also an established marker for liver iron deposition. Aim of the Work: The aim of this study is to configurate the distribution of iron and ferritin levels in patients with chronic hepatitis C virus infection and to conduct a comparative study between the pretreatment and the post treatment iron profile after direct acting antiviral therapies in chronic HCV patients. Patients and Methods: This Randomized Controlled Clinical study was conducted on 100 subjects aged from 18 to 60 years selected from Gastroenterology and Hepatology department at Ain Shams University Hospital, Cairo, Egypt, from January 2017 to April 2017 and was approved by the ethical committee. Results: The current study suggests that a 12 weeks course of Sofosbuvir / Ledipasvir combination drug therapies showed a higher SVR 12 (92 %) and have significant decrease of the elevated serum iron and ferritin and transferrin saturation to the normal level more than sofosbuvir / Daclatasvir which showed a SVR 12 (88%). In both study groups, patients who showed SVR had significant lower values of Iron, Ferritin and transferrin saturation levels than patients who were non-SVR after end of therapy. Conclusion: This study may also shed light on how the changes in serum iron and ferritin levels in chronic hepatitis C patients may be related to HCV treatment. Recommendations: Sofosbuvir / Ledipasvir 12-weeks course is more recommended than Sofosbuvir / Daclatasvir 12 weeks course in patients with chronic HCV infection. As serum Iron, serum Ferritin and Transferrin saturation showed more significant improvement with SOF/LED combination therapy than SOF/DAC combination therapy, they are a good markers of highly predictive value in treatment of chronic HCV infected patients with DAAs.
INTRODUCTION
Hepatitis C virus (HCV) infection which affects nearly 2% of the human population is a major cause of liver disease worldwide. Following acute HCV infection chronicity is 80%. Although many individuals carrying the virus remain asymptomatic, chronicity is accompanied by altered liver function and progressive liver disease ending in cirrhosis or hepatocellular carcinoma in up to 20% of infected subjects (1) . Mild -to -moderate iron overload is a common finding among patients with chronic HCV infection where up to 30-40% of them may show increased serum transferrin-iron saturation and serum ferritin or increased hepatic iron concentration (2) . Elevated iron indices is correlated with progression of liver disease and a decreased response to antiviral therapy (3, 4) . Excess iron increases the formation of reactive oxygen species (hydroxyl radicals) leading to lipid peroxidation and damage to protein and DNA resulting in cell membrane and genomic damage and hepatic stellate cell activation and proliferation and upregulate synthesis of smooth muscle actine and collagen thus leading to hepatic fibrogenesis (5) . Moreover, iron deposition in hepatocytes enhances HCV replication thus facilitating the viral infection in the liver (6) . These hydroxyl radicals generate promutagenic substances such as 8-hydroxyl-2`-deoxy-gusuosine (8-0HDG) which have been implicated in spontaneous DNA mutagenesis and carcinogenesis (7) . Therefore, there is need to configurate the distribution of iron and ferritin levels in patients with chronic HCV.
AIM OF THE WORK
The aim of this study is to configurate the distribution of iron and ferritin levels in patients with chronic hepatitis C virus infection and to conduct a comparative study between the pretreatment and the post treatment iron profile after direct acting antiviral therapies in chronic HCV patients.
PATIENTS AND METHODS

Study Design
This study was a Randomized Controlled Clinical Trial conducted on 100 subjects aged from 18 to 60 years selected from Gastroenterology and Hepatology department at Ain Shams University Hospital, Cairo, Egypt, 1519 from January 2017 to April 2017 and was approved by the ethical committee.
The subjects were allocated randomly and have been invited to participate in the study after taking a complete informed written consent. The subjects of both sex were divided into: Group : includes 50 patients who were positive for HCV antibodies and positive for HCV RNA (Diseased group), they were classified as a diseased group who have been subdivided into: 
Group
Statistical Analysis of the data
Data Management and Analysis:
The collected was revised, coded, tabulated and introduced to a PC using statistical package for social sciences IBM SPSS 20.0. Data was presented and suitable analysis was done according to the type of data obtained for each parameter. Table ( 4) shows that there is a statistically significant decrease in serum Iron, Ferritin and Transferrin saturation level after administraion of therapy in the group Ia, (p < 0.05). with no statistically significant decrease in transferrin level after administration of therapy (p > 0.05). Table ( 6) shows that there is a significantly highly elevated values of iron, ferritin, transferrin, and transferrin saturation between Group Ia (SOF/DAC), Group Ib (SOF/LED) > group (control group) before administration of therapy (P < 0.05). 
I. Descriptive Statistics
Socio-demographic data
Figure (4): Comparison between Group Ia (SOF/DAC) and Group Ib (SOF/LED) as regard Serum Transferrin levels after administration of therapy
Figure (4) shows that there is no statistically significant decrease in Serum Transferrin level after administration of therapy (P>0.05) in group and group Table ( 9) shows that there is no statistically significant difference between Group (SOF/DAC) and Group (SOF/LED) as regard HCV PCR before start of therapy as well as after completion of treatment (P>0.05). Additionally both groups had no statistically significant difference after treatment in each group; however each group showed highly significant decline in the mean quantitative value of HCV PCR after end of therapy. Table ( 10) shows that in the group Ia, the patients who showed SVR had significant lower values of Iron, Ferritin and Transferrin saturation levels than patients who were non-SVR after end of therapy. (p< 0.05). with no decrease in transferrin level (p > 0.05). Table ( 11) shows that in the group Ib, the patients who showed SVR had significant lower values of Iron, Ferritin and Transferrin saturation levels than patients who were non-SVR after end of therapy, (p < 0.05). with no decrease in transferrin level (p > 0.05)
DISCUSSION
The current work was prepared to compare between serum iron together with serum ferritin and transferrin saturation levels in 100 subjects, of both sex, who have been divided into two; the diseased group concluded 50 patients who were positive for HCV antibodies and positive for HCV RNA and the control group which contained 50 subjects with matched age and sex who were negative for HCV antibodies. Furthermore, the diseased group was subdivided into 2 other groups as regard specific treatment agents (25 patients who received Sofosbuvir 400 mg orally once daily plus Daclatasvir 60 mg orally once daily for 12 weeks (group ΙA) versus 25 patients who received Sofosbuvir 400 mg orally once daily + Ledipasvir 90 mg orally once daily for 12 weeks (group ΙB). Up to the knowledge till now there was no study had been carried out to compare serum iron and ferritin in Sofosbuvir / Daclatasvir versus Sofosbuvir / Ledipasvir combination drug therapies group patients.
In the current study there was no statistically significant difference regarding Age between both groups, ( , there was no statistically significant difference regarding Gender between both groups, (table 8), (P > 0.05), this is in agreement with Abdel Latif et al.
(8)
; and there was no statistically significant difference regarding Marital state between both groups, (table 8), (P > 0.05).
Before treatment the mean value of iron was noted to be elevated and matched in both study groups, no statistically significant difference was existed between diseased groups, (table 14) , but was not elevated in the control subjects group , (table 13) . The results were in agreement with Bazeed et al.
(10) who reported that before start therapy, no statistically significant difference was existed between group who received sofosbuvir, interferon and ribavirin. After treatment there was significant decrease regarding the values of serum iron in both groups to normal values, with more decrease of serum iron in group 1b than group 1a (table 15, figure 1 ). This is in contrast to Bazeed et al.
(10) who revealed in his study that, in case of patients treated with Sofosbuvir, ribavirin and pegylated interferon for 12 weeks, a significant increase in serum iron level after treatment but it did not reach the upper limit of normal.
These results were explained in the same study by the shorter duration of interferon therapy compared to the old regimen of 48 weeks, so little hepcidin (the iron regulatory hormone) production resulting in little reduction in serum iron. Also, this increase in serum iron may be due to ribavirin induced hemolytic anemia that increases serum iron because red blood cells are being destroyed too quickly
; This is in agreement with Bernutha et al.
(12) who noticed Serum iron, despite being also decreased, no significant difference was revealed (p = 0.117) Before treatment the mean value of serum ferritin was noted to be elevated and matched in both study groups, no statistically significant difference was existed between group 1a and 1b, (p> 0.05), (table 14) , but was not elevated in the control healthy subjects group , (table 13) . The results were in agreement with Bazeed et al.
(10) who reported that before start therapy, no statistically significant difference was existed between groups who received sofosbuvir, interferon and ribavirin. After treatment there was significant decrease regarding the values of serum ferritin in both groups to normal values, (p< 0.05), (table 15, figure 2), with more decrease of serum ferritin in group 1b than group 1a,. The results were in agreement with Bazeed et al.
(10) who reported that the group received sofosbuvir showed an extremely significant lower value of serum ferritin than the normal control group.
Also, the study is in agreement with Bernutha et al (12) who has noted a reduction in serum ferritin levels from baseline to end of therapy (p < 0.001) Before treatment the mean value of Transferrin level and saturation were noted to be elevated and matched in both study groups, no statistically significant difference was existed between group 1a and 1b, (p > 0.05), (table 14) , but was not elevated in the control healthy subjects group , ( , who noticed no statistically significat difference as regard serum transferrin level and saturation in groups before treatment. After treatment there was significant decrease regarding the values of serum transferrin saturation level in both groups to normal values, with more decrease in group 1b than group 1a, (p< 0.05), (table 15, figure 3 ), but with no statistically significant difference between group 1a and group 1b as regard serum transferrin level after therapy, (p> 0.05), (table 15, figure 4), this is in contrast to Bernutha et al , who noticed transferrin saturation showed normal values at both time points (baseline = 28.9% and SVR12 = 27.3%, respectively) and therefore decreased by 5.5% (p = 0.071). Transferrin increased from 2.81 to 2.97 g/l (p = 0.583).
Bitar and Dbaibo
(2) reported that mild-tomoderate iron overload is a common finding among patients with chronic HCV infection; indeed, up to 30-40% of them may show increased serum transferrin-iron saturation and serum ferritin or increased hepatic iron concentration. On the other hand, elevated iron indices have been correlated with a progression of the liver disease and a decreased response to antiviral therapy
(13)
. In current study it was denoted that LED/SOF combination has favorable adverse effect profile not leading to drug discontinuation like fatigue, headache, nausea, diarrhea, and insomnia, which is in agreement with European Association for the Study of Liver 2015
(14)
. The group Ia, SVR 12 was 88 % Versus SVR 12 was 92 % in group 1b, the patients who showed SVR in both groups, had significant lower values of Iron, Ferritin and Transferrin level, Transferrin saturation levels than patients who were non-SVR after end of therapy, ( . This current study is in agreement with Abd El Latif et al.
(8)
, who noticed that SVR 12 was achieved by 90 % in group received sofosbuvir / simeprevir regimen and 77 % in group received sofosbuvir / ribavirin regimen. Also, in agreement with Willemse et al. (16) , who noticed that SVR 12 was 92 % in group received sofosbuvir / simeprevir regimen for 12 weeks. There was no statistically significant difference between both groups regarding the baseline and after treatment Hb level, (p> 0.05), (table 9, 10). This is in agreement with Abd El Latif et al.
, who noticed that Hb doesn't fall down in group taking sofosbuvir / semiprevir versus group received sofosbuvir / ribavirin who showed significant decrease in Hb due to ribavirin hemolytic anemia which is one of the most significant adverse reaction of ribavirin.
There was no statistically significant difference in platelets count before and after treatment in both studied groups, (p> 0.05), (table 9, 10), this is in agreement with Gane et al. , who noticed no change in platelets count throughout his study on sofosbuvir / ribavirin regimen. But in contrast to Ruane et al. , who noticed that the platelets count increased during treatment with sofosbuvir / ribavirin regimen and in contrast to Apurva et al. There was no statistically significant difference in Total leucocytic count before and after treatment in both studied groups, (p > 0.05), ( There was no statistically significant difference in Bilirubin before and after treatment in both studied groups, (p > 0.05), (table 9, 10), this is in agreement with Abd El Latif et al. , who noticed no statistically significant difference between both groups (sofosbuvir / simeprevir group & sofosbuvir / ribavirin) and in contrast to Apurva et al.
(19) who noticed increased bilirubin with sofosbuvir / semiprevir regimen.
There was no statistically significant difference regarding ALT and AST before and after treatment in both studied groups, (p > 0.05), (table 9, who noticed no statistically significant difference between study groups regarding the baseline and end-of-treatment levels of ALT and AST, who discovered also elevation in ALT and AST during treatment with sofosbuvir / simeprevir regimen which is higher than ontreatment with sofosbuvir / ribavirin regimen.
CONCLUSION
Results of the current study suggest that a 12 weeks course of Sofosbuvir / Ledipasvir combination drug therapies showed a higher SVR 12 (92 %) and have significant decrease of the elevated serum iron and ferritin and transferrin saturation to the normal level more than sofosbuvir / Daclatasvir which showed a SVR 12 (88 %). In both study groups, patients who showed SVR had significant lower values of Iron, Ferritin and Transferrin saturation levels than patients who were non-SVR after end of therapy.
This study may also shed light on how the changes in serum iron and ferritin levels in chronic hepatitis C patients may be related to HCV treatment.
RECOMMENDATIONS
Sofosbuvir/Ledipasvir 12-weeks course is more recommended than Sofosbuvir / Daclatasvir 12 weeks course in patients with chronic HCV infection. As serum Iron, serum Ferritin and Transferrin saturation showed more significant improvement with SOF/LED combination therapy than SOF/DAC combination therapy, they are a good markers of highly predictive value in treatment of chronic HCV infected patients with DAAs. Further prospective randomized trials should be performed to find the role of serum iron and ferritin to predict the response of treatment with 12 -weeks course of Sofosbuvir / Ledipasvir or 12-weeks course of Sofosbuvir / Daclatasvir combination drug therapies.
